Table 2.

Clinical and laboratory parameters during the study coursea

WeekCandesartan, 32 mg(n = 15)Candesartan, 64 mg(n = 17)P
Systolic BP (mmHg)
    run-in0136 ± 13135 ± 17NS
    first 16 mg candesartan4132 ± 20137 ± 20NS
    high-dose candesartan16132 ± 15130 ± 21bNS
    second 16 mg candesartan20129 ± 12131 ± 13NS
Diastolic BP (mmHg)
    run-in084 ± 985 ± 7NS
    first 16 mg candesartan485 ± 1485 ± 9NS
    high-dose candesartan1685 ± 1180 ± 11b,cNS
    second 16 mg candesartan2083 ± 1083 ± 8NS
Creatinine clearance (ml/min)
    run-in096 ± 38106 ± 65NS
    first 16 mg candesartan498 ± 42107 ± 68NS
    high-dose candesartan1697 ± 4898 ± 63NS
    second 16 mg candesartan2094 ± 52102 ± 66NS
Urinary sodium excretion (mol/d)
    run-in0218 ± 93286 ± 112NS
    first 16 mg candesartan4221 ± 93245 ± 101dNS
    high-dose candesartan16255 ± 83236 ± 103cNS
    second 16 mg candesartan20235 ± 97249 ± 98NS
  • a All data are expressed as mean ± SD. P values in the table are given for comparison between treatment groups (t test). Within groups the following analyses were performed and are highlighted by superscript letters (one symbol: P < 0.05; two symbols: P < 0.01):

  • b high-dose candesartan phase versus first 16 mg candesartan phase;

  • c high-dose candesartan phase versus run-in phase;

  • d first 16 mg candesartan phase versus run-in phase.